×

We've got news for you.

Register on SowetanLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

IP waiver won’t improve Africa’s access to Covid-19 shots: global drug makers

Vaccines are in plentiful supply but poorer countries lack capacity to administer jabs, say companies

Pharmaceutical companies producing Covid-19 vaccines say lack of infrastructure rather than patent barriers stand in the way of Africa’s access to jabs. File photo.
Pharmaceutical companies producing Covid-19 vaccines say lack of infrastructure rather than patent barriers stand in the way of Africa’s access to jabs. File photo.
Image: Reuters/DADO RUVIC

Multinational pharmaceutical companies have criticised the push by SA and India to introduce an intellectual property (IP) waiver on Covid-19 vaccines. They say lack of infrastructure rather than patent barriers stand in the way of Africa’s access to jabs.

SA and India launched a campaign 18 months ago for the World Trade Organisation to waive patents on Covid-19 vaccines, tests and treatments for the duration of the pandemic to enable large-scale production of cheap generics.

Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations, said on Wednesday vaccine nationalism, export bans and lack of support for international vaccine-sharing mechanism Covax were responsible for last year’s inequitable distribution of shots, which saw Africa sent to the back of the queue.

“These were the causes of vaccine inequity last year, and not as many would wish you to believe, something that can be solved with a waiver on IP on Covid-19 products,” he said in an online press briefing.

The problem had shifted as Covid-19 vaccines were in plentiful supply, but poorer countries lacked the capacity to administer the jabs, he said.

“Countries as well as organisations such as Africa CDC are not only asking for orders to be delayed, but are cancelling them.  

“I am stunned that the IP waiver is still debated while supplies far outstrip demand. IP has never been a hindrance to scaling up vaccine manufacturing, but has been an enabler of tech transfer and other forms of voluntary licensing.”

Weakening patents sent the wrong signal to investors, he said.

Hundreds of activists and non-profit organisations wrote this week to President Cyril Ramaphosa and Indian Prime Minister Narendra Modi, urging them to reject a compromise deal struck in February by negotiators for the US, EU, India and SA that limits the waiver to Covid-19 vaccines.

They said the leaked text favoured the interests of the US and EU at the expense of developing countries.

More than 100 countries initially backed the plan flighted by SA and India in October 2020. The US has since shifted its position to supporting a waiver solely for vaccines, a view shared by New Zealand and Australia.

Pharmaceutical companies that hold patents on Covid-19 vaccines and treatments have opposed the proposed waiver from the outset.

Eli Lilly CEO Dave Ricks said the global pharmaceutical industry produced more than a billion Covid-19 vaccines a month.

“It is not a supply problem, or a demand problem, but a matching of the two. An IP waiver will do nothing to change that,” he said.

The global pharmaceutical industry could develop vaccines and treatments for the pandemic at unprecedented speed thanks to the international patent framework which gave companies confidence to invest in underlying technology that had been repurposed to tackle Covid-19, he said.

BusinessLIVE


Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.